You are here
Articles
Posted on Friday, September 27, 2013 - 12:36pm
Treatment of chronic myeloid leukemia (CML) has evolved considerably in recent years. Chemotherapy with hydroxyurea and busulfan were the main options for many years, and although these agents can control hematologic...
Posted on Wednesday, August 7, 2013 - 1:07pm
J E Kim1,7, S Yoon1,7, B-R Choi1, K P Kim2, Y-H Cho3, W Jung4, D-W Kim5, S Oh6 and D-E Kim1
The BCR–ABL fusion transcript encodes the BCR–ABL tyrosine kinase (TK), which causes chronic myelogenous leukemia (CML)....
Posted on Monday, July 29, 2013 - 2:34pm
Ahmad Hamad, Zeyad Sahli, Maya El Sabban, Maha Mouteirik, and Rihab Nasr
Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon
13...
Posted on Friday, July 26, 2013 - 5:16pm
By Dave Levitan
June 14, 2013
Almost half of patients with chronic-phase chronic myeloid leukemia (CML) who discontinued imatinib(Drug information on imatinib) treatment did not relapse, according to results of a...
Posted on Friday, July 26, 2013 - 5:04pm
By Michael Mauro, MD1, Jerald Radich, MD2
July 25, 2013
1Memorial Sloan-Kettering Cancer Center, New York
2Fred Hutchinson Cancer Research Center, Seattle
Interviewed by Anna Azvolinsky, PhD
Chronic...
Posted on Monday, July 15, 2013 - 1:25pm
By Dave Levitan | July 12, 2013
While tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) in recent years, prognosis of the disease and prediction of response to those...
Posted on Friday, July 5, 2013 - 10:59am
Read the report from the 11th International Conference for Organisations Representing People with CML.
Posted on Wednesday, July 3, 2013 - 12:44pm
Zosia Chustecka
Jul 02, 2013
The European Commission has granted marketing authorization to ponatinib (Iclusig, Ariad Pharmaceuticals) as an orphan drug for use in certain leukemia patients who have stopped responding...
Posted on Monday, July 1, 2013 - 12:13pm
Michele Baccarani1,*, Michael W. Deininger2, Gianantonio Rosti3, Andreas Hochhaus4, Simona Soverini3, Jane F. Apperley5, Francisco Cervantes6, Richard E. Clark7, Jorge E. Cortes8, François Guilhot9, Henrik Hjorth-...
Posted on Monday, June 17, 2013 - 3:18pm
The Chronic Myelogenous Leukemia (CML) Society of Canada is pleased to provide open access to the paper, “Treating Chronic Myeloid Leukemia - Improving Management Through Understanding of the Patient Experience”.
Posted on Wednesday, June 12, 2013 - 10:45am
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP)
2013...
Posted on Wednesday, June 12, 2013 - 10:38am
2013 ASCO Annual Meeting
Abstract Number: 7079
Citation: J Clin Oncol 31, 2013 (suppl; abstr 7079)
Author(s):
Hemant Malhotra, Pratibha Sharma, Shipra Bhargava, Om Singh Rathode, Bharti Malhotra, Vikram...
Posted on Wednesday, June 5, 2013 - 10:53am
" The tyrosine kinase inhibitors (TKIs) have irrevocably changed the care of chronic myeloid leukemia (CML) patients, dramatically changing the natural history of this disease.1-4 With multiple TKIs available, we now...
Posted on Wednesday, June 5, 2013 - 10:03am
Significance
Cancer stem cells (CSCs) frequently acquire the ability to self-renew and persist in their hosts by coopting normal stem cell programs. Blast crisis (BC) chronic myeloid leukemia is a prototypic example, as...
Posted on Saturday, June 1, 2013 - 9:14pm
Sebastian Francis, Claire Lucas, Steven Lane, Lihui Wang, Sarah Watmough, Katy Knight, Jo Bell, Mohammed Kaleel-Rahman, Edwin Lee, David O’Brien, Nauman M. Butt, Walid Sadik, Lally De Soysa, Jim R.C. Seale, Rahuman...
- ‹ previous
- 10 of 29
- next ›